Adicet Bio (DE:1IJ)
FRANKFURT:1IJ
1IJ Stock Chart & Stats
€5.55
--
Market closed
€5.55
--
Day’s Range― - ―
52-Week Range€5.05 - €15.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€55.51M
Enterprise Value€40.72M
Total Cash (Recent Filing)€158.53M
Total Debt (Recent Filing)€14.74M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
May 12, 2026EPS Estimate
-9.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.52
Shares Outstanding9,596,407
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€32.52Price Target Upside485.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-27.85
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / SolvencyAdicet's low debt-to-equity (~0.09) meaningfully limits near-term solvency risk and preserves financial optionality. For a cash-burning clinical-stage biotech, low leverage reduces refinancing pressure, allows flexibility in structuring partner deals, and lowers near-term bankruptcy risk if development timelines slip.
Regulatory Alignment For Outpatient DosingFDA agreement to permit outpatient dosing represents a structural operational improvement: it simplifies trial logistics, can lower trial costs, broadens eligible patient pools and supports faster enrollment. Over 2–6 months this materially improves execution probability for clinical milestones and commercial design.
Extended Cash Runway From Equity RaiseThe ~ $74.8M raise lengthens runway into H2 2027, giving management time to deliver planned 2026 clinical updates and advance ADI-212 toward an H1 2026 regulatory filing target. This reduces immediate dilution pressure and provides a multi-quarter window to achieve de‑risking milestones.
Bears Say
No Commercial RevenueThe absence of recurring product revenue leaves the company fully dependent on external financing and partner milestones. Over the medium term this elevates execution risk: delays or negative trial results would sharply reduce cash inflows and could force dilutive financings or program cuts.
Persistent Negative Cash FlowSustained large negative operating and free cash flow implies ongoing reliance on capital markets to fund R&D. Persistent annual outflows of this scale increase the probability of further equity raises, diluting existing holders, and constrain strategic optionality if clinical progress is slower than planned.
Erosion Of Shareholder Equity & Poor ReturnsMaterial erosion of the equity base and sharply negative ROE reflect cumulative cash burn and losses, weakening the firm's capital buffer. This trend reduces resilience to adverse outcomes, increases sensitivity to financing market conditions, and signals persistent inability to convert R&D investment into near-term economic returns.
Adicet Bio News
1IJ FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest stock price was €5.05 and its highest was €15.00 in the past 12 months.
What is Adicet Bio’s market cap?
Adicet Bio’s market cap is €55.51M.
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is May 12, 2026 which is in 28 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Mar 12, 2026. The company reported -€2.516 earnings per share for the quarter, missing the consensus estimate of -€2.49 by -€0.026.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio does not currently pay dividends.
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -9.41.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 9,596,407 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -€2.516 in its last earnings report, missing expectations of -€2.49. Following the earnings report the stock price went down -5.691%.
Which hedge fund is a major shareholder of Adicet Bio?
Currently, no hedge funds are holding shares in DE:1IJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€32.52 (485.88% Upside)
€32.52 (485.88% Upside)
Blogger Sentiment
Bullish
DE:1IJ Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $929.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.49%
12-Months-Change
Fundamentals
Return on Equity
-82.96%
Trailing 12-Months
Asset Growth
-12.65%
Trailing 12-Months
Company Description
Adicet Bio
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
1IJ Stock 12 Month Forecast
Average Price Target
€32.52
▲(485.88% Upside)